New Approval for Zykadia (LDK378/ceritinib) in ALK-Positive NSCLC: Why It Matters Even if You're Not ALK-Positive
Article
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.
[powerpress]
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock